Drug Trial Radar · NCT02571036
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Dec 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
282
Actual
Start
Nov 2015
Primary completion
Apr 29, 2022
Study completion Apr 29, 2022
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.
Conditions
- Gastrointestinal Stromal Tumors
- Advanced Systemic Mastocytosis
- Advanced Cancers
Interventions
DCC-2618Drug
50 mg formulated tablets
DCC-2618Drug
10 mg and 50 mg formulated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety/tolerability of oral DCC-2618: incidence of adverse eventsTime frame: Approximately 24 months
- Determination of the Maximum Tolerated Dose and the Recommended Phase 2 DoseTime frame: 18 months
- Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseasesTime frame: Approximately 24 months
Locations
26 sites in 6 countries. Site status is shown where the registry gives one.
Honor Health (GIST, mastocytosis, other solid tumors)
Scottsdale, Arizona
UCLA Hematology Center (mastocytosis)
Los Angeles, California
UCLA (glial malignancies only)
Los Angeles, California
Stanford University Comprehensive Cancer Center (GIST)
Palo Alto, California
Stanford University Hematology Clinic (mastocytosis)
Palo Alto, California
UCSF (glial malignancies only)
San Francisco, California
Mayo Clinic (GIST, mastocytosis, glial malignancies, other solid tumors)
Jacksonville, Florida
University of Miami (GIST, mastocytosis, glial malignancies, other solid tumors)
Miami, Florida
Dana Farber Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)
Boston, Massachusetts
Colombia University Medical Center (mastocytosis)
New York, New York
Memorial Sloan Kettering Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)
New York, New York
OHSU (GIST & mastocytosis only)
Portland, Oregon
Fox Chase Cancer Center (GIST only)
Philadelphia, Pennsylvania
MD Anderson Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors)
Houston, Texas
Huntsman Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors)
Salt Lake City, Utah
Virginia Commonwealth University School of Medicine (mastocytosis)
Richmond, Virginia
Princess Margaret Cancer Centre (GIST, other solid tumors)
Toronto, Canada
Uniklinik RWTH Aachen (mastocytosis, GIST, and other solid tumors)
Aachen, Germany
HELIOS Klinikum Berlin-Buch (GIST, and other solid tumors)
Berlin, Germany
Essen University Hospital (mastocytosis, GIST, and other solid tumors)
Essen, Germany
Freiburg University Hospital (mastocytosis, and other solid tumors)
Freiburg im Breisgau, Germany
University Medical Centre Mannheim (mastocytosis)
Mannheim, Germany
University Hospital of Verona (mastocytosis)
Verona, Italy
Leiden University Medical Center (GIST and other solid tumors)
Leiden, Netherlands
Guy's Hospital (mastocytosis only)
London, United Kingdom
Royal Marsden Hospital (GIST, glial malignancies, other solid tumors)
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.